Opus Genetics, Inc. Research And Development Expense

• Opus Genetics, Inc. showed a decrease of -58.2% in Research And Development Expense from 2018 to 2019.
• This data is from Opus Genetics, Inc.'s annual report (Form 10-K), filed with the SEC on February 21, 2020.
• XBRL data for this metric is available from 2009 to 2019 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2010: $1.33 million | Q3 2010: $671.3 thousand | Q1 2011: $2.72 million | Q2 2011: $5.42 million | Q3 2011: $2.37 million | Q1 2012: $1.04 million | Q2 2012: $1.02 million | Q3 2012: $1.07 million | Q1 2013: $552.5 thousand | Q2 2013: $925.1 thousand | Q3 2013: $781.3 thousand | Q1 2014: $1.27 million | Q2 2014: $1.70 million | Q3 2014: $1.82 million | Q1 2015: $2.89 million | Q2 2015: $3.24 million | Q3 2015: $3.10 million | Q1 2016: $3.47 million | Q2 2016: $2.24 million | Q3 2016: $2.30 million | Q1 2017: $2.26 million | Q2 2017: $2.54 million | Q3 2017: $2.64 million | Q1 2018: $4.06 million | Q2 2018: $3.43 million | Q3 2018: $2.89 million | Q1 2019: $2.24 million | Q2 2019: $1.65 million | Q3 2019: $1.13 million | Q1 2020: $456.8 thousand | Q2 2020: $231.6 thousand | Q3 2020: $149.6 thousand.
• Over the full 11 years of available data (2009 to 2019), Opus Genetics, Inc.'s Research And Development Expense has grown by 72.4%.
• Historical annual values: Fiscal year 2019: $5.48 million | Fiscal year 2018: $13.11 million | Fiscal year 2017: $10.72 million | Fiscal year 2016: $10.09 million | Fiscal year 2015: $12.15 million | Fiscal year 2014: $7.02 million | Fiscal year 2013: $3.25 million | Fiscal year 2012: $3.39 million | Fiscal year 2011: $11.99 million | Fiscal year 2010: $3.93 million | Fiscal year 2009: $3.18 million.
• Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: August 6, 2026